Eupraxia Pharmaceuticals (NASDAQ:EPRX) Releases Earnings Results, Beats Expectations By $0.02 EPS

Eupraxia Pharmaceuticals (NASDAQ:EPRX) announced its earnings results on Tuesday. The company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.02, Zacks reports.

Eupraxia Pharmaceuticals Trading Up 2.7%

Shares of NASDAQ:EPRX traded up $0.17 during trading on Thursday, reaching $6.65. The company’s stock had a trading volume of 75,125 shares, compared to its average volume of 267,773. The stock has a market capitalization of $432.58 million, a PE ratio of -6.52 and a beta of 1.08. Eupraxia Pharmaceuticals has a 12 month low of $5.04 and a 12 month high of $9.32. The firm’s 50 day simple moving average is $6.41 and its two-hundred day simple moving average is $7.16. The company has a current ratio of 19.31, a quick ratio of 19.31 and a debt-to-equity ratio of 0.02.

Hedge Funds Weigh In On Eupraxia Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in EPRX. Guardian Wealth Advisors LLC NC bought a new position in shares of Eupraxia Pharmaceuticals during the fourth quarter valued at approximately $76,000. Aptus Capital Advisors LLC bought a new position in shares of Eupraxia Pharmaceuticals during the fourth quarter valued at approximately $76,000. Integrated Wealth Concepts LLC purchased a new stake in Eupraxia Pharmaceuticals during the third quarter worth $71,000. Bank of America Corp DE lifted its stake in shares of Eupraxia Pharmaceuticals by 402.4% during the 2nd quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock worth $72,000 after purchasing an additional 10,059 shares during the last quarter. Finally, Geode Capital Management LLC bought a new stake in shares of Eupraxia Pharmaceuticals in the 4th quarter valued at about $105,000.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Stifel Nicolaus began coverage on Eupraxia Pharmaceuticals in a research report on Thursday, May 21st. They issued a “buy” rating and a $25.00 price target for the company. Wall Street Zen downgraded Eupraxia Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 16th. Cantor Fitzgerald reissued an “overweight” rating on shares of Eupraxia Pharmaceuticals in a report on Wednesday, July 15th. Zacks Research raised Eupraxia Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Thursday, May 7th. Finally, HC Wainwright reissued a “buy” rating and issued a $11.00 price objective on shares of Eupraxia Pharmaceuticals in a research note on Monday, May 4th. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Eupraxia Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $18.00.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.